Crispr Therapeutics AG (CRSP)
Healthcare
Biotechnology
49.60 $
+3.3%
vs. previous close
Closing price · As of: 3. Aug 2026
Crispr Therapeutics AG (CRSP) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -345 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.8 | 59 | -55 | -70 | -96 | 57 | -238 | 539 | -496 | -260 | -143 | -345 | |
| 0.0 | 0.1 | 0.9 | 3.0 | 3.5 | 4.7 | 9.2 | 18 | 24 | 20 | 19 | 19 | |
| 0.7 | 3.7 | 11 | 19 | 35 | 44 | 66 | 102 | 98 | 81 | 87 | 72 | |
| -0.1 | 3.4 | -35 | 21 | 35 | 50 | 68 | 102 | 110 | – | – | – | |
| 1.5 | 81 | 1.8 | -25 | 11 | -48 | 33 | 27 | 20 | -194 | 156 | 72 | |
| 1.2 | 1.2 | 3.0 | 7.8 | 2.8 | 6.7 | 18 | 82 | 37 | 9.5 | 1.9 | 0.9 | |
| -1.2 | -1.2 | 32 | -8.3 | -2.8 | 1.3 | -541 | -1,035 | -259 | 375 | -280 | -32 | |
| – | – | 0.0 | 0.0 | – | – | – | – | – | – | – | – | |
| 0.0 | 59 | 115 | 2.6 | -0.1 | 431 | 1,016 | 251 | 39 | – | – | 71 | |
| 38 | 38 | 35 | – | – | – | – | – | – | – | – | – | |
| 5.1 | 97 | 183 | 2.6 | 316 | 431 | 1,016 | 251 | 39 | 63 | 332 | 426 | |
| 0.6 | 155 | 160 | -76 | 217 | 489 | 237 | -246 | -716 | 178 | -91 | 49 | |
| -4.8 | 58 | -58 | -78 | -99 | 50 | -257 | 457 | -533 | -270 | -145 | -346 |
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.